Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 10Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Prostatic Neoplasms 2Liposarcoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Pancreatic Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Endometrial Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1

Interventions

tucatinib 1pembrolizumab 1niraparib 1atezolizumab 1Trastuzumab 1Tissue Banks 1GSK-3326595 1Fulvestrant 1Etoposide 1Diet 1Cyclophosphamide 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Fulvestrant × Thoracic × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡